<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03464968</url>
  </required_header>
  <id_info>
    <org_study_id>biliary second line</org_study_id>
    <nct_id>NCT03464968</nct_id>
  </id_info>
  <brief_title>mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line</brief_title>
  <official_title>A Randomized Phase II Study of mFOLFOX vs. mFOLFIRI in Advanced or Recurrent Biliary Tract Cancer Refractory to First Line Gemcitabine Plus Cisplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In second line with advanced or recurrent biliary tract cancer refractory to first line
      gemcitabine plus cisplatin, efficacy of mFOLFOX vs. mFOLFIRI will be evaluated at randomized
      phase 2 trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. brief enrollment criteria

             -  histological confirmed

             -  refractory to first line gemcitabine plus cisplatin

             -  fit for chemotherapy

        2. treatment arms A. mFOLFOX D1 oxaliplatin 100mg/m2 over 2hr Leucovorin 100mg/m2 over 2hr
           5FU 2400mg/m2 over 46hr Every 2 weeks

           B. mFOLFIRI D1 Irinotecan 150mg/m2 over 2hr Leucovorin 100mg/m2 over 2hr 5FU 2400mg/m2
           over 46hr Every 2 weeks

        3. randomization - stratified by tumor site and performance status
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2015</start_date>
  <completion_date type="Anticipated">December 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 25, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6 months overall survival rate</measure>
    <time_frame>6months</time_frame>
    <description>at 6 months from intervention treatment, overall survival rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
    <time_frame>6months</time_frame>
    <description>complete response, partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>6months</time_frame>
    <description>complete response, partial response, stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>6months</time_frame>
    <description>from treatment start to progression or any cause of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Related Adverse Events as Assessed by NCI CTC version 4.0</measure>
    <time_frame>6months</time_frame>
    <description>percentage of all patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Biliary Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>mFOLFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D1 oxaliplatin 100mg/m2 over 2hr Leucovorin 100mg/m2 over 2hr 5FU 2400mg/m2 over 46hr Every 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mFOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D1 Irinotecan 150mg/m2 over 2hr Leucovorin 100mg/m2 over 2hr 5FU 2400mg/m2 over 46hr Every 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin,5FU, leucovorin</intervention_name>
    <description>mFOLFOX</description>
    <arm_group_label>mFOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan,5FU, leucovorin</intervention_name>
    <description>mFOLFIRI</description>
    <arm_group_label>mFOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20 years and older

          -  pathologically confirmed biliary tract cancer (adenocarcinoma) including intrahepatic,
             extrahepatic, gallbladder, ampulla of vater

          -  initially inoperable or recurrent

          -  ECOG 0-2

          -  as first line chemotherapy, refractory to gemcitabine/cisplatin (at least one cycle
             applied)

          -  evaluable or measurable lesion

          -  within 1 week, patients who meet below laboratory results (hemoglobin &gt;9.0 g/dL,
             neutrophil &gt;1000/uL, platelet&gt; 75000/uL, serum creatinine &lt; UNL * 1.5, AST/ALT &lt;
             UNL*3, total bilirubin &lt; UNL*1.5 (available for biliary drainage)

          -  patients who have ability to understand the purpose, benefit and harm for this trial,
             and the right to withdraw this trial in any time without any disadvantage

        Exclusion Criteria:

          -  other cancer history

          -  pregnant or lactating

          -  uncontrolled medical condition such as infection or cardiovascular disease

          -  hypersensitivity to experimental drugs

          -  uncontrolled CNS metastasis, psychologic problem
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jin Won Kim, MD, PhD</last_name>
    <phone>82 031 787 7053</phone>
    <email>jwkim@snubh.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Won Kim, MD, PhD</last_name>
      <phone>82-31-787-8209</phone>
      <email>jwkim@snubh.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Jin Won Kim</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <keyword>second line</keyword>
  <keyword>FOLFOX</keyword>
  <keyword>FOLFIRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

